Chargement en cours...
Bortezomib for the treatment of mantle cell lymphoma: an update
Bortezomib is a first in class proteasome inhibitor, initially approved by the US Food and Drug Administration for the treatment of plasma cell myeloma. Bortezomib has been approved for the treatment of relapsed and refractory mantle cell lymphoma (MCL) and, more recently, in the upfront setting as...
Enregistré dans:
| Publié dans: | Ther Adv Hematol |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959639/ https://ncbi.nlm.nih.gov/pubmed/27493710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716648566 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|